* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI al...
* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing th...
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified t...
* Insilico Medicine merges nebulizer device with AI-driven drug discovery; * Potential advantage...
* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discov...
NEW YORK, May 17, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage generative artificial in...
NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage artificia...
Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 ...
* Insilico and its collaborators scoured massive datasets and found genes relevant to ALS through...
NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial in...
* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, ...
NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end a...